What are the indications, recommended dosing regimens, contraindications, and common adverse effects of Utrogestan (micronized progesterone)?

Utrogestan (Micronized Progesterone): Clinical Overview

Primary Indications

Utrogestan is indicated for endometrial protection in postmenopausal women with an intact uterus receiving estrogen therapy, and for threatened abortion in the first trimester. 1, 2

• Endometrial protection: Oral micronized progesterone 200 mg daily for 12–14 days per month (sequential regimen) or 100 mg daily continuously provides adequate endometrial protection when combined with estrogen therapy, reducing endometrial cancer risk by approximately 90% compared to unopposed estrogen. 1, 3, 4

• Threatened abortion: Utrogestan 400 mg daily (200 mg twice daily orally) for at least 14 days (average 21 days) has been used successfully in women with first-trimester threatened abortion, with 90% (61/68) maintaining healthy pregnancies without side effects. 2

• Dysfunctional uterine bleeding: Vaginal administration of 600 mg daily (3 tablets twice daily) starting on day 14 of the menstrual cycle for 12 days has demonstrated effectiveness in premenopausal women aged 40–49 years. 5

Recommended Dosing Regimens

For Hormone Replacement Therapy (Endometrial Protection)

Sequential regimen (preferred for women accepting withdrawal bleeding):

• Oral micronized progesterone 200 mg at bedtime for 12–14 consecutive days per 28-day cycle, combined with continuous transdermal estradiol 50–100 μg daily. 1, 3, 4
• The 12–14 day duration is critical—shorter durations provide inadequate endometrial protection and increase endometrial cancer risk by approximately 1.8-fold. 1, 3

Continuous regimen (preferred for women desiring amenorrhea):

• Oral micronized progesterone 100–200 mg at bedtime taken daily without interruption, combined with continuous estradiol. 1, 4

Vaginal administration (off-label):

• Vaginal micronized progesterone 200 mg nightly for 12–14 consecutive days per 28-day cycle may provide endometrial protection for up to 3–5 years, though this is off-label use. 1, 3
• Vaginal progesterone 4% gel (45 mg/day) or 100 mg every other day for at least 10 days/month has been studied but requires careful monitoring. 3

For Threatened Abortion

• Oral: 400 mg daily (200 mg twice daily) for at least 14 days, with average treatment duration of 21 days. 2
• In severe cases, initial dosing may be increased to 400–600 mg daily (two tablets two or three times daily). 2

For Dysfunctional Uterine Bleeding

• Vaginal: 600 mg daily (3 tablets twice daily) starting on day 14 of the menstrual cycle for 12 days, continued for 6 months. 5

Absolute Contraindications

Utrogestan is contraindicated in the following conditions:

• Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels. 1, 6
• Antiphospholipid syndrome or positive antiphospholipid antibodies. 1, 6
• Personal history of breast cancer (any receptor status). 1, 6
• Active or prior venous thromboembolism or pulmonary embolism. 1, 6
• History of stroke or transient ischemic attack. 1, 6
• Established coronary heart disease or prior myocardial infarction. 1, 6
• Known thrombophilic disorders (e.g., inherited hypercoagulable states). 1, 6
• Unexplained vaginal bleeding. 1, 6
• Pregnancy (when used for hormone replacement therapy). 7
• Hypersensitivity to progesterone or any component of the formulation. 7

Common Adverse Effects

The most frequently reported adverse effects are mild and transient:

• Drowsiness/sedation: The most specific side effect, minimized by taking the medication at bedtime. 4
• Headache and dizziness: Reported in particular cases, especially with morning administration. 2
• Gastrointestinal symptoms: Nausea, abdominal discomfort, and bloating may occur. 7
• Breakthrough bleeding: May occur during the first 3–6 months of sequential therapy; switching to continuous daily dosing often resolves this. 1

Serious adverse events (rare):

• Decidual cast (strongest signal in pharmacovigilance data). 8
• Meningioma (newly identified association with long-term use >6 months). 9, 8
• Autoimmune dermatitis and acute eosinophilic pneumonia (rare newly identified events). 8

Critical Clinical Considerations

Duration of progesterone exposure is the critical factor for endometrial protection:

• Sequential regimens must provide at least 12 days of progesterone per cycle; durations shorter than 10 days are associated with a 1.8-fold increase in endometrial cancer risk. 1, 3
• Oral micronized progesterone provides endometrial protection for up to 5 years when used sequentially at 200 mg/day for 12–14 days/month. 3

Route-specific considerations:

• Transdermal micronized progesterone does NOT provide endometrial protection and should not be used for this indication. 3
• Vaginal administration achieves therapeutic serum progesterone concentrations while potentially reducing systemic side effects (drowsiness, mood changes) compared with oral dosing. 1

Timing with estrogen therapy:

• Progesterone must be added to any estrogen therapy in women with an intact uterus; unopposed estrogen increases endometrial cancer risk 10- to 30-fold after 5+ years (relative risk 2.3–9.5). 1, 6
• For women with premature ovarian insufficiency, begin cyclic progesterone only after at least 2 years of estrogen therapy alone or when breakthrough bleeding occurs. 1

Common Pitfalls to Avoid

• Never use progesterone for fewer than 12 days per cycle in sequential regimens—this provides inadequate endometrial protection. 1, 3
• Never prescribe estrogen alone to women with an intact uterus—this dramatically increases endometrial cancer risk. 1, 6
• Never assume transdermal progesterone provides endometrial protection—only oral and vaginal routes are effective. 3
• Do not continue hormone therapy beyond the period needed for symptom control—breast cancer risk escalates after >5 years of combined estrogen-progesterone use. 1, 6
• Avoid prescribing to women >60 years or >10 years post-menopause without compelling indication—the risk-benefit profile becomes unfavorable. 1, 6

Monitoring Requirements

• Annual clinical review focusing on compliance, bleeding patterns, symptom control, and emergence of new contraindications. 1, 6
• No routine laboratory monitoring (hormone levels) is required; management is symptom-based. 1, 6
• Endometrial surveillance (ultrasound/biopsy) is unnecessary when progesterone is taken correctly; any abnormal bleeding warrants evaluation. 1, 6
• For off-label vaginal regimens, consider baseline and annual endometrial ultrasound to document endometrial thickness. 9

Alternative Progestogen Options

If micronized progesterone is not tolerated or unavailable:

• Medroxyprogesterone acetate (MPA): 10 mg daily for 12–14 days per month (sequential) or 2.5–5 mg daily continuously is the most extensively studied alternative, though it has a less favorable cardiovascular and metabolic profile. 1, 9
• Norethindrone acetate: 1 mg daily offers superior cardiovascular and metabolic outcomes compared to MPA while maintaining excellent endometrial protection. 9
• Dydrogesterone: 10 mg daily for 12–14 days per month (sequential) or 5 mg daily continuously is endorsed by ESHRE as an alternative, though evidence in premature ovarian insufficiency populations is limited. 1, 9
• Levonorgestrel intrauterine system: Delivers progestogen directly to the uterus, providing reliable endometrial protection with fewer systemic adverse effects, particularly useful for patients experiencing systemic progestogen side effects. 9